

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

On page 291, please replace the paragraph beginning on line 26 with the following new paragraph:

In preferred embodiments, the fragment or variant of an antibody that specifically binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, an scFv comprising the VH domain of the Therapeutic antibody, linked to the VL domain of the therapeutic antibody by a peptide linker such as (Gly₄Ser)₃ (SEQ ID NO: [[36]] 72).

On page 481, please replace the paragraph beginning on line 7 with the following new paragraph:

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTTCCCCCAAACCCAA
GGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGACGTA
AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTG
GTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGT
GCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTCCAAGC
CAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGA
GCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGC
GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACC
ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCG
TGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA

GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
GTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO: [[36]] 73)

On page 507, please replace the paragraph beginning on line 16 with the following new paragraph:

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995)). A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xaa-Trp-Ser (SEQ ID NO: [[37]] 74)).

On page 509, please replace the paragraph beginning on line 9 with the following new paragraph:

5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCG
AAATGATTTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO: [[38]] 75)

On page 509, please replace the paragraph beginning on line 11 with the following new paragraph:

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO: [[39]] 76)

On page 509, please replace the paragraph beginning on line 17 with the following new paragraph:

5':CTCGAGATTTCCTCCCGAAATCTAGATTTCCTCCCGAAATGATTTCCTCCCGAAAT
GATTTCCTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTA
ACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATG
GCTGACTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTTGGAGGCCTAGGCTTTTGCAAAAAAGCTT:3'
(SEQ ID NO: [[40]] 77)

On page 512, please replace the paragraph beginning on line 10 with the following new paragraph:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG-3' (SEQ ID NO: [[41]] 78)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO: [[42]] 79)

Please replace the paragraph bridging pages 514 and 515, beginning on line 36 on page 514, with the following new paragraph:

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGACTTTCCC) (SEQ ID NO: [[43]] 80), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGA
CTTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO: [[44]] 81)

On page 515, please replace the paragraph beginning on line 8 with the following new paragraph:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO: [[39]] 76)

On page 515, please replace the paragraph beginning on line 13 with the following new paragraph:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCC
GCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTT
TTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTCCAGAAGTAGTG
AGGAGGCTTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO: [[45]] 82)